mebeverine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
spasmolytics with a papaverine-like action 1642 3625-06-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mebeverine
  • mebeverine hydrochloride
  • CSAG 144
  • mebeverine HCl
  • Molecular weight: 429.56
  • Formula: C25H35NO5
  • CLOGP: 5.23
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 0
  • TPSA: 57.23
  • ALOGS: -5.17
  • ROTB: 14

Drug dosage:

DoseUnitRoute
0.30 g O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vision blurred 46.85 22.22 42 3383 79666 46602971
Abdominal pain 35.85 22.22 62 3363 229969 46452668
Visual impairment 35.00 22.22 33 3392 66656 46615981
Lagophthalmos 33.48 22.22 7 3418 288 46682349
Upper gastrointestinal haemorrhage 31.60 22.22 18 3407 16720 46665917
Abnormal loss of weight 30.30 22.22 12 3413 4963 46677674
Coma scale abnormal 30.23 22.22 12 3413 4994 46677643
Chest pain 29.39 22.22 49 3376 176275 46506362
Hypertonia 28.00 22.22 11 3414 4455 46678182
Blood blister 25.57 22.22 8 3417 1660 46680977
Serotonin syndrome 25.50 22.22 18 3407 24202 46658435
Swollen tongue 24.64 22.22 19 3406 29213 46653424
Macroglossia 24.06 22.22 6 3419 544 46682093
False positive investigation result 23.99 22.22 6 3419 550 46682087
Mouth ulceration 23.84 22.22 18 3407 26814 46655823
Pressure of speech 23.74 22.22 6 3419 574 46682063
Myalgia 22.92 22.22 36 3389 123052 46559585

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Arthropod sting 52.87 30.24 9 1056 254 29951159
Eye infection 45.49 30.24 12 1053 2830 29948583
Irritable bowel syndrome 45.04 30.24 12 1053 2940 29948473
Somnambulism 44.03 30.24 12 1053 3202 29948211
Abdominal pain 39.62 30.24 35 1030 135619 29815794
Metastatic malignant melanoma 39.24 30.24 10 1055 2060 29949353
Lower respiratory tract infection 30.24 30.24 16 1049 26698 29924715

Pharmacologic Action:

SourceCodeDescription
ATC A03AA04 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Synthetic anticholinergics, esters with tertiary amino group
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Irritable bowel syndrome indication 10743008 DOID:9778

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.31 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D04868 KEGG_DRUG
2753-45-9 SECONDARY_CAS_RN
C0065832 UMLSCUI
CHEBI:91514 CHEBI
CHEMBL282121 ChEMBL_ID
CHEMBL1446650 ChEMBL_ID
DB12554 DRUGBANK_ID
C005096 MESH_SUPPLEMENTAL_RECORD_UI
17683 PUBCHEM_CID
9011 IUPHAR_LIGAND_ID
1191 INN_ID
7F80CC3NNV UNII
235827 RXNORM
003995 NDDF
003996 NDDF
349819003 SNOMEDCT_US
395779008 SNOMEDCT_US
419830007 SNOMEDCT_US

Pharmaceutical products:

None